Acutaas Chemicals Q3 FY26 Revenue Jumps 43% YoY to ₹3,932mn, PAT Surges 133.7% to ₹1,062mn
Acutaas Chemicals reported a 43.0% YoY increase in Q3 FY26 revenue to ₹3,932 million (393.2 crore) and a 133.7% YoY surge in PAT to ₹1,062 million (106.2 crore). The company revised its full-year revenue growth guidance to approximately 30% from 25%. Management is scaling battery and semiconductor chemical verticals.
The significant increase in revenue and profit, coupled with a revised positive growth forecast and strategic expansion into high-growth sectors like battery and semiconductor chemicals, suggests a material positive impact on the company's financial performance and market position.
The company reported strong year-on-year growth in revenue, profits, and margins across key financial metrics for Q3 FY26. The upward revision of revenue guidance and positive commentary on strategic growth areas indicate a favorable outlook.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a significant year-on-year growth in revenue from operations, which increased by 43.0% to ₹3,932 million (393.2 crore) in Q3 FY26, compared to ₹2,750 million (275 crore) in Q3 FY25. The Gross Profit saw a substantial rise of 76.1% YoY to ₹2,240 million (224 crore), with Gross Margin improving to 57.0% from 46.2% in the prior year period. EBITDA grew by 119.4% YoY to ₹1,507 million (150.7 crore), and EBITDA Margin expanded to 38.3% from 25.0% YoY. The Profit After Tax (PAT) crossed the ₹1,000 million milestone, reaching ₹1,062 million (106.2 crore), a remarkable increase of 133.7% YoY. The PAT Margin also improved significantly to 27.0% from 16.5% YoY. For the nine months ended December 31, 2025, revenue from operations grew by 29.8% YoY to ₹9,066 million (906.6 crore), and PAT increased by 127.3% YoY to ₹2,221 million (222.1 crore).
Mr. Naresh Patel, Executive Chairman & Managing Director, highlighted the company's strategy to reinforce its core pharmaceutical intermediates business while scaling up battery chemicals and semiconductor chemicals verticals. These new businesses are under active capital investment and are expected to become self-sustaining growth engines within three years. He also noted the strong growth momentum driven by the ramp-up of the CDMO business. Based on a healthy order book and improved visibility, the company has revised its revenue growth guidance upward for the financial year from 25% to approximately 30%.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.